First-in-India Experience with 90Y-BhabhaSphere: An Indigenous 90Y-TheraSphere Biosimilar for Transarterial radioembolization of Hepatic Malignancies.

Objective: Primary and secondary hepatic malignancies are a significant cause of cancer-related mortality worldwide. Radioembolization with yttrium-90 (90Y) microspheres has emerged as a promising treatment option for unresectable hepatic tumors. However, the high cost of commercially available Y-90 microspheres, such as 90Y-TheraSphere or 90Y-SirSphere, limits their accessibility in developing countries.

Multi-dose formulation and clinical deployment of [Y]Y-labeled hydroxyapatite (HA) microparticles for radiation synovectomy in India- the inherent intricacies.

The present article describes intricate details involved in the formulation and quality control of 113 ready to use doses of [Y]Y-labeled hydroxyapatite (HA) microparticles for clinical use in radiation synovectomy using Y produced by (n,γ) route. Yttrium-90 was produced with a specific activity of 720 ± 95 MBq/mg of Y and radionuclidic purity of >99.9%.

pH-Responsive magnetic nanocarriers for chelator-free bimodal (MRI/SPECT-CT) image-guided chemo-hyperthermia therapy in human breast carcinoma.

Although chemotherapy with magnetic nanocarriers has witnessed significant advancement in the field of cancer treatment, multimodal diagnosis and combinatorial therapy using a single nanoplatform will have much better efficacy in achieving superior results. Herein, we constructed a smart theranostic system by combining pH-sensitive tartaric acid-stabilized FeO magnetic nanocarriers (TMNCs) with SPECT imaging and a chemotherapeutic agent for image-guided chemo-hyperthermia therapy. The carboxyl-enriched exteriors of TMNCs provided sites for the conjugation of a chemotherapeutic drug (doxorubicin hydrochloride, DOX) and radiolabeling (Ce).

[ 64 Cu]Copper chloride PET-CT: a comparative evaluation of fasting and non-fasting states in patients of prostate carcinoma.

Altered copper metabolism in cancer has been linked to increased intracellular copper uptake mediated by human copper transporter 1, with [ 64 Cu]Cu 2+ as a potential biomarker for cancer theranostics. [ 64 Cu]CuCl 2 PET-CT though explored in various malignancies, a lack of standardized protocol exists, particularly regarding fasting status before imaging. This analysis aimed to evaluate the requirement of fasting for [ 64 Cu]CuCl 2 PET-CT along with temporal changes in physiological organ uptake in delayed scans.

[Y]Yttria Alumino Silicate Glass Microspheres: A Biosimilar Formulation to "TheraSphere" for Cost-Effective Treatment of Liver Cancer.

Selective internal radiation therapy (SIRT) using a suitable β-emitting radionuclide is a promising treatment modality for unresectable liver carcinoma. Yttrium-90 (Y) [ = 64.2 h, (max) = 2.